TYK2 kinase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “TYK2 Kinase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
TYK2 Kinase Inhibitors: Overview
Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.
Report Highlights
This segment of the TYK2 Kinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TYK2 Kinase Inhibitors Emerging Drugs
Further product details are provided in the report……..
TYK2 Kinase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TYK2 Kinase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
TYK2 Kinase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TYK2 Kinase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TYK2 Kinase Inhibitors drugs.
TYK2 Kinase Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “TYK2 Kinase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
TYK2 Kinase Inhibitors: Overview
Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TYK2 Kinase Inhibitors R&D. The therapies under development are focused on novel approaches for TYK2 Kinase Inhibitors.
This segment of the TYK2 Kinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TYK2 Kinase Inhibitors Emerging Drugs
- Deucravacitinib: Bristol-Myers Squibb
- Brepocitinib: Pfizer
Further product details are provided in the report……..
TYK2 Kinase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TYK2 Kinase Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on TYK2 Kinase Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
TYK2 Kinase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TYK2 Kinase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TYK2 Kinase Inhibitors drugs.
TYK2 Kinase Inhibitors Report Insights
- TYK2 Kinase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing TYK2 Kinase Inhibitors drugs?
- How many TYK2 Kinase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for TYK2 Kinase Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the TYK2 Kinase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TYK2 Kinase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Incyte Corporation
- Bristol-Myers Squibb
- Oncostellae
- Pfizer
- Galapagos
- Haisco Pharmaceutical Group
- Sareum
- Oncostellae
- Baricitinib
- Deucravacitinib
- OST-122
- Brepocitinib
- GLPG-3121
- FTP 637
- SDC-1801
- OST-246
Introduction
Executive Summary
TYK2 Kinase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
TYK2 Kinase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TYK2 Kinase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TYK2 Kinase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Deucravacitinib: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Brepocitinib: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
GLPG-3121 Galapagos
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
FTP 637: Haisco Pharmaceutical Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TYK2 Kinase Inhibitors Key Companies
TYK2 Kinase Inhibitors Key Products
TYK2 Kinase Inhibitors- Unmet Needs
TYK2 Kinase Inhibitors- Market Drivers and Barriers
TYK2 Kinase Inhibitors- Future Perspectives and Conclusion
TYK2 Kinase Inhibitors Analyst Views
TYK2 Kinase Inhibitors Key Companies
Appendix
Executive Summary
TYK2 Kinase Inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
TYK2 Kinase Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
TYK2 Kinase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TYK2 Kinase Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Deucravacitinib: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Brepocitinib: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
GLPG-3121 Galapagos
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
FTP 637: Haisco Pharmaceutical Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
TYK2 Kinase Inhibitors Key Companies
TYK2 Kinase Inhibitors Key Products
TYK2 Kinase Inhibitors- Unmet Needs
TYK2 Kinase Inhibitors- Market Drivers and Barriers
TYK2 Kinase Inhibitors- Future Perspectives and Conclusion
TYK2 Kinase Inhibitors Analyst Views
TYK2 Kinase Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for TYK2 Kinase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for TYK2 Kinase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for TYK2 Kinase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for TYK2 Kinase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
